Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)

Abstract Background The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have significantly improved outcomes for patients with HER2-posit...

Full description

Bibliographic Details
Main Authors: Gavin P. Dowling, Sinead Toomey, Philip Bredin, Imelda Parker, Eibhlin Mulroe, Jacinta Marron, Olivia McLoughlin, Ausra Teiserskiene, Colm Power, Anne Marie O’Shea, Megan Greally, Patrick G. Morris, Deirdre Duke, Arnold D. K. Hill, Bryan T. Hennessy
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Breast cancer
Trastuzumab deruxtecan
HER2-positive
Neoadjuvant
Pathological Complete Response
Online Access:https://doi.org/10.1186/s12885-024-11851-4

Internet

https://doi.org/10.1186/s12885-024-11851-4

Similar Items